Rexahn’s goal is to be a world-class biopharmaceutical company developing and delivering novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Leveraging a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling and nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.
Our passion is to discover and develop new medicines for diseases that plague patients with no effective cures, in particular high mortality cancers and CNS disorders.
Rexahn’s core scientific expertise in signal transduction is producing a drug portfolio with significant potential clinical value. From the onset our research determined that by “tuning” the cell signaling pathways to shut down uncontrolled cell growth resulting in cancer, we could similarly tune the cell signaling pathways related to CNS-based conditions as Parkinson’s, Alzheimer’s, depression and sexual dysfunction.
Consequently, we believe that our drugs have the potential to change the paradigm of how some cancers and CNS disorders are treated, not only providing patients with new cures, but also hope for a better quality of life.
Today, our clinical pipeline features multiple Phase II drugs that we believe will fill a void of viable therapies for diseases where a meaningful cure is overdue.
Serdaxin® a best-in-class therapy for treating depression, and potentially Parkinson’s Disease and Alzheimer’s Disease.
Zoraxel™ a first-in-class CNS-based therapy for treating sexual dysfunction.
Archexin® a first-in-class AKT-inhibitor therapy for treating various cancers, such as pancreatic cancer, renal cell carcinoma (RCC), glioblastoma, and cancers of the ovary and stomach.
These lead clinical drugs are part of a robust pipeline that includes several promising pre-clinical anti-cancer compounds.
Our strategy is to continue building a significant product pipeline of innovative medicines that we will commercialize alone or with pharma partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating bio-pharmaceutical company – one with the expertise to develop cures for the major diseases of our time.